Strategies for Receptor inhibition in immunotherapy

免疫治疗中的受体抑制策略

• 批准号: 10379372
• 负责人: Michael Lawrence Dougan
• 金额: $ 36.78万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10379372
• 关键词: Address; Affinity; Animals; Anti-CD47; Autoimmune; Award; Back; Binding; Biochemical; Biological; Bispecific Antibodies; Blocking Antibodies; CD47 gene; CTLA4 gene; Cell surface; Clinical; Clinical Trials; Collection; Colon; Colonic inflammation; Combination immunotherapy; Dimerization; Drug Targeting; Eating; Engineering; Exhibits; Extracellular Domain; Goals; Grant; Homeostasis; Human; ITAM; ITIM; Immune; Immune response; Immune system; Immunologic Receptors; Immunotherapeutic agent; Immunotherapy; In Vitro; Inflammatory; Insulin-Dependent Diabetes Mellitus; Interleukin-2; Ligand Binding; Ligands; Ligation; Link; MC38; Malignant neoplasm of pancreas; Mediating; Modality; Modeling; Molecular; Monoclonal Antibodies; Mus; Myelogenous; Myeloid Cells; Oncology; Organoids; PD-1 blockade; PTPNS1 gene; PTPRC gene; Patients; Performance; Phosphoric Monoester Hydrolases; Phosphotransferases; Play; Production; Protein Dephosphorylation; Protein Engineering; Proteins; Receptor Inhibition; Receptor Signaling; Role; Signal Transduction; Structure-Activity Relationship; System; T-Cell Activation; T-Lymphocyte; Technology; Therapeutic; Therapeutic antibodies; Toxic effect; Treatment Efficacy; Tumor Antibodies; Tumor Cell Line; Tumor Immunity; Tumor-Derived; Tyrosine Phosphorylation; antagonist; anti-PD-1; anti-PD1 antibodies; base; bench to bedside; cancer therapy; cancer type; checkpoint inhibition; checkpoint receptors; cytokine; dimer; effector T cell; extracellular; immune checkpoint blockade; improved; in vivo; in vivo evaluation; interest; lung small cell carcinoma; macrophage; melanoma; mouse model; novel; novel strategies; novel therapeutics; programmed cell death ligand 1; programmed cell death protein 1; receptor; receptor-mediated signaling; recruit; tumor

Abstract: Despite the recent advances in immunotherapy, such as checkpoint blockade, radical new approaches are needed to both improve the efficacy of existing treatments, and to offer entirely new therapeutic modalities. In the previous term of this award we developed an immunotherapeutic agent that exploited the myeloid branch of the immune system by blocking the SIRPa/CD47 axis, potentiating macrophage attack on tumors. We engineered a unique, high-affinity SIRPa antagonist of CD47 that greatly potentiated the anti-tumor efficacy of several clinically approved anti-tumor antibodies, yet offered the advantage of being tumor selective and non- toxic, which is a limitation of most current anti-CD47 mAbs. This molecule is now in clinical trials for several cancer types, thus completing the cycle of bench to bedside in one term of the award. In this renewal application, we request support to develop a new paradigm for receptor inhibition in oncology. We present a new approach to immune checkpoint blockade (ICB), and antagonizing the CD47/SIRPa axis, by exploiting an untapped natural biological mechanism for dampening immune receptor signaling. We have found that ITIM/ITAM/ITSM/ITTM-containing immunoreceptors, such as the checkpoint receptors PD1 and CTLA4, tonically signal in the absence of ligand engagement. As a result, blocking PD-L1 binding with anti-PD1 antibodies, does not fully “take the brakes off” of T cell activation: ligand-independent PD1 tonic signaling significantly blunts T cell activation. We have devised a strategy reduce or eliminate tonic signaling, termed Receptor Inhibition by Phosphatase Recruitment (RIPR), that relies on the cis-ligation of kinases-mediated signaling receptors to a cell surface phosphatase, such as CD45, to achieve complete signal inhibition through intracellular dephosphorylation of the target receptor intracellular ITAM/ITIM/ITSM/ITTM domains. RIPR molecules are bi- specific antibodies that compel dimerization of a target receptor to a cell-surface phosphatase, inhibiting both ligand binding and tonic signaling. Using the PD1 system as our first target, we find that we achieve significantly greater inhibition of checkpoint blockade using a RIPR that dimerizes PD1 with the T cell phosphatase CD45, versus ligand blocking by anti-PD1 antibodies. Furthermore, we see enhanced therapeutic efficacy over anti- PD1 in several mouse tumor models. In this proposal we seek support to better understand the mechanism of RIPR at the biochemical and cellular level, to assess its therapeutic efficacy in a range of mouse tumor models both alone and in combination with therapeutic antibodies, and to explore RIPR applications beyond checkpoint inhibition to other receptors, such as CTLA4 and SIRPa, that are oncology drug targets.

摘要： 尽管最近在免疫治疗方面取得了进展，例如检查点阻断，但仍有一些激进的新方法被发现。 需要既提高现有治疗的疗效，又提供全新的治疗方式。在 在该奖项的前一个学期，我们开发了一种免疫抑制剂，利用骨髓分支， 通过阻断SIRPa/CD 47轴，增强巨噬细胞对肿瘤的攻击，增强免疫系统。我们 设计了一种独特的、高亲和力的CD 47 SIRPa拮抗剂，大大增强了 几种临床批准的抗肿瘤抗体，但具有肿瘤选择性和非肿瘤性的优点 毒性，这是目前大多数抗CD 47 mAb的局限性。这种分子现在正在进行几项临床试验， 癌症类型，从而完成周期的板凳到床边在一个任期的奖项。在这次更新申请中， 我们请求支持开发肿瘤学中受体抑制的新范例。我们提出了一种新的方法 免疫检查点阻断（ICB），并拮抗CD 47/SIRPa轴，通过利用未开发的 抑制免疫受体信号传导的天然生物学机制。我们发现 含有ITIM/ITAM/ITSM/ITTM的免疫受体，如检查点受体PD 1和CTLA 4， 在没有配体接合的情况下的信号。因此，用抗PD 1抗体阻断PD-L1结合， T细胞活化未完全“松开刹车”：配体非依赖性PD 1紧张性信号传导显著减弱 T细胞活化。我们设计了一种减少或消除紧张性信号传导的策略，称为受体抑制， 磷酸酶募集（RIPR），依赖于激酶介导的信号受体与细胞的顺式连接 表面磷酸酶，如CD 45，以通过细胞内信号传导实现完全的信号抑制 靶受体胞内ITAM/ITIM/ITSM/ITTM结构域的去磷酸化。RIPR分子是双- 特异性抗体，迫使靶受体二聚化为细胞表面磷酸酶，抑制两者 配体结合和紧张性信号传导。使用PD 1系统作为我们的第一个目标，我们发现我们实现了显着 - 使用使PD 1与T细胞磷酸酶CD 45二聚化的RIPR对检查点阻断的更大抑制， 与抗PD 1抗体的配体阻断相比。此外，我们还看到了比抗- PD 1在几种小鼠肿瘤模型中的表达。在本提案中，我们寻求支持，以更好地了解 RIPR在生化和细胞水平，以评估其在一系列小鼠肿瘤模型中的治疗效果 单独使用和与治疗性抗体联合使用，并探索RIPR在检查点之外的应用 抑制其他受体，例如CTLA 4和SIRPa，这些受体是肿瘤学药物靶点。